• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

How Much Can We Bet on Activity of BET Inhibitors Beyond NUT-Midline Carcinoma?

作者信息

Martin-Romano Patricia, Baldini Capucine, Postel-Vinay Sophie

机构信息

DITEP (Département d'Innovations Thérapeutiques et Essais Précoces), Gustave Roussy, Villejuif, France.

Université Paris Saclay, Université Paris-Sud, Faculté de médicine, Le Kremlin Bicêtre, France.

出版信息

JNCI Cancer Spectr. 2019 Nov 6;4(2):pkz092. doi: 10.1093/jncics/pkz092. eCollection 2020 Apr.

DOI:10.1093/jncics/pkz092
PMID:32328560
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7165801/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ca/7165801/63a5709b869a/pkz092f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ca/7165801/63a5709b869a/pkz092f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e6ca/7165801/63a5709b869a/pkz092f1.jpg

相似文献

1
How Much Can We Bet on Activity of BET Inhibitors Beyond NUT-Midline Carcinoma?除NUT中线癌外，我们对BET抑制剂的活性还能寄予多大期望？
JNCI Cancer Spectr. 2019 Nov 6;4(2):pkz092. doi: 10.1093/jncics/pkz092. eCollection 2020 Apr.
2
Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.双重选择性溴结构域抑制剂 NEO2734 对 NUT 中线癌中 BRD4-NUT-p300 轴的联合靶向作用
Mol Cancer Ther. 2020 Jul;19(7):1406-1414. doi: 10.1158/1535-7163.MCT-20-0087. Epub 2020 May 5.
3
NUT midline carcinoma of the head and neck: current perspectives.头颈部 NUT 中线癌：当前观点
Onco Targets Ther. 2019 Apr 30;12:3235-3244. doi: 10.2147/OTT.S173056. eCollection 2019.
4
Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases.NUT中线癌治疗模式及预后因素对结局的影响：119例患者的系统评价与个体患者数据分析
Eur Arch Otorhinolaryngol. 2018 Mar;275(3):815-821. doi: 10.1007/s00405-018-4882-y. Epub 2018 Jan 22.
5
Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.靶向 p300/CBP HAT 结构域治疗 NUT 中线癌。
Oncogene. 2020 Jun;39(24):4770-4779. doi: 10.1038/s41388-020-1301-9. Epub 2020 May 4.
6
Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.NUT 癌的临床病理和临床前研究：一项多中心研究。
Oncologist. 2019 Aug;24(8):e740-e748. doi: 10.1634/theoncologist.2018-0477. Epub 2019 Jan 29.
7
Small-Molecule Targeting of BET Proteins in Cancer.小分子靶向 BET 蛋白治疗癌症。
Adv Cancer Res. 2016;131:21-58. doi: 10.1016/bs.acr.2016.04.001. Epub 2016 May 31.
8
NUT Carcinoma-An Underdiagnosed Malignancy.NUT癌——一种诊断不足的恶性肿瘤。
Front Oncol. 2022 Jul 26;12:914031. doi: 10.3389/fonc.2022.914031. eCollection 2022.
9
Bromodomain and extra-terminal inhibitors-A consensus prioritisation after the Paediatric Strategy Forum for medicinal product development of epigenetic modifiers in children-ACCELERATE.溴结构域和末端外结构域抑制剂-儿童表观遗传修饰药物开发儿科战略论坛共识优先级-ACCELERATE。
Eur J Cancer. 2021 Mar;146:115-124. doi: 10.1016/j.ejca.2021.01.018. Epub 2021 Feb 16.
10
NUT midline carcinoma: Current concepts and future perspectives of a novel tumour entity.NUT 中线癌：一种新型肿瘤实体的当前概念和未来展望。
Crit Rev Oncol Hematol. 2019 Dec;144:102826. doi: 10.1016/j.critrevonc.2019.102826. Epub 2019 Nov 1.

引用本文的文献

1
Placental metastasis from maternal NUT carcinoma: diagnostic pitfalls and challenges.胎盘转移的母体 NUT 癌：诊断陷阱与挑战。
BMJ Case Rep. 2024 Apr 2;17(4):e259538. doi: 10.1136/bcr-2023-259538.
2
Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma.一名不可切除的鼻窦 NUT 癌患者在接受免疫治疗后对 BET 抑制剂产生持续临床反应。
J Immunother Precis Oncol. 2024 Feb 5;7(1):67-72. doi: 10.36401/JIPO-23-19. eCollection 2024 Feb.
3
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a Trial.

本文引用的文献

1
An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients.睾丸核蛋白（NUT）中线癌患者的解剖部位和基于基因的预后模型：124例患者分析
JNCI Cancer Spectr. 2019 Nov 6;4(2):pkz094. doi: 10.1093/jncics/pkz094. eCollection 2020 Apr.
2
Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors.溴结构域和额外末端结构域蛋白抑制剂莫利西布（GSK525762）在NUT癌和其他实体瘤中的1期研究
JNCI Cancer Spectr. 2019 Nov 6;4(2):pkz093. doi: 10.1093/jncics/pkz093. eCollection 2020 Apr.
3
BMS-986158，一种溴结构域和额外末端结构域蛋白的小分子抑制剂，用于特定晚期实体瘤患者：1/2a期试验结果
Cancers (Basel). 2022 Aug 23;14(17):4079. doi: 10.3390/cancers14174079.
4
Therapeutic impact of BET inhibitor BI 894999 treatment: backtranslation from the clinic.BET 抑制剂 BI 894999 治疗的疗效影响：临床回译。
Br J Cancer. 2022 Aug;127(3):577-586. doi: 10.1038/s41416-022-01815-5. Epub 2022 Apr 20.
5
Nuclear protein of the testis midline carcinoma of the thorax.胸部中线型精原细胞瘤核蛋白。
Jpn J Clin Oncol. 2022 May 31;52(6):531-538. doi: 10.1093/jjco/hyac033.
6
Epigenetic Modulation of Radiation-Induced Diacylglycerol Kinase Alpha Expression Prevents Pro-Fibrotic Fibroblast Response.辐射诱导的二酰基甘油激酶α表达的表观遗传调控可预防促纤维化成纤维细胞反应。
Cancers (Basel). 2021 May 18;13(10):2455. doi: 10.3390/cancers13102455.
7
BET inhibitors repress expression of interferon-stimulated genes and synergize with HDAC inhibitors in glioblastoma.BET 抑制剂抑制干扰素刺激基因的表达，并与组蛋白去乙酰化酶抑制剂在神经胶质瘤中协同作用。
Neuro Oncol. 2021 Oct 1;23(10):1680-1692. doi: 10.1093/neuonc/noab115.
Combining epigenetic drugs with other therapies for solid tumours - past lessons and future promise.
将表观遗传学药物与其他疗法联合用于实体瘤——过去的经验教训和未来的前景。
Nat Rev Clin Oncol. 2020 Feb;17(2):91-107. doi: 10.1038/s41571-019-0267-4. Epub 2019 Sep 30.
4
Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies.开发具有不同药代动力学和药效学特征的 2 溴结构域和末端外结构域抑制剂，用于治疗晚期恶性肿瘤。
Clin Cancer Res. 2020 Mar 15;26(6):1247-1257. doi: 10.1158/1078-0432.CCR-18-4071. Epub 2019 Sep 16.
5
First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.在复发/难治性实体瘤患者中进行的口服多溴结构域和末端蛋白（BET）抑制剂 Mivebresib（ABBV-075）的首次人体研究。
Clin Cancer Res. 2019 Nov 1;25(21):6309-6319. doi: 10.1158/1078-0432.CCR-19-0578. Epub 2019 Aug 16.
6
Protein-slaying drugs could be the next blockbuster therapies.蛋白质杀伤药物可能成为下一批重磅疗法。
Nature. 2019 Mar;567(7748):298-300. doi: 10.1038/d41586-019-00879-3.
7
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.首例人体 I 期研究：溴结构域和末端外结构域抑制剂 BAY 1238097：新出现的药代动力学/药效学关系和因意外毒性而提前终止。
Eur J Cancer. 2019 Mar;109:103-110. doi: 10.1016/j.ejca.2018.12.020. Epub 2019 Jan 31.
8
Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of the Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression.发现 QCA570 可作为一种极其有效和强效的溴结构域和额外末端（BET）蛋白的蛋白水解靶向嵌合体（PROTAC）降解剂，能够诱导完全和持久的肿瘤消退。
J Med Chem. 2018 Aug 9;61(15):6685-6704. doi: 10.1021/acs.jmedchem.8b00506. Epub 2018 Jul 18.
9
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.Birabresib 联合治疗晚期实体瘤的 Ib 期临床试验：一种新型小分子溴结构域和末端外结构域蛋白抑制剂
J Clin Oncol. 2018 Oct 20;36(30):3007-3014. doi: 10.1200/JCO.2018.78.2292. Epub 2018 May 7.
10
BET Proteins as Targets for Anticancer Treatment.BET 蛋白作为抗癌治疗的靶点。
Cancer Discov. 2018 Jan;8(1):24-36. doi: 10.1158/2159-8290.CD-17-0605. Epub 2017 Dec 20.